Thrombosis risk in systemic lupus erythematosus: The role of thrombophilic risk factors

Scandinavian Journal of Rheumatology

Volumn 36, Issue 3, 2007, Pages 198-205

  Sallai, K K ^a   Nagy, E ^a   Bodo I ^a   Mohl, A ^a   Gergely, P ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; GLYCOPROTEIN; HOMOCYSTEINE; PROTEIN C; PROTEIN S; PROTHROMBIN A; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CAUCASIAN; CONFIDENCE INTERVAL; EVOLUTIONARY ADAPTATION; FEMALE; GENE MUTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCREENING; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; VEIN THROMBOSIS;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR V; FACTOR VIII; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MUTATION; RISK FACTORS; THROMBOPHILIA; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 34547470036     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740601089283     Document Type: Article

References (47)

1. Marai I, Zandman-Goddard G, Shoenfeld Y. The systemic nature of the antiphospholipid syndrome. Scand J Rheumatol 2004;33:365-72.
2. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003;1:931-42.
3. Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002;90:29-37.
4. Pierangeli SS, Harris EN. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus 2003;12:539-45.
5. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res 2004;114:321-7.
6. Giesen PLA, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311-15.
7. Mok CC. Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand J Rheumatol 2006;35:85-95.
8. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107:I-9-16.
9. Brouwer JLP, Bijl M, Veeger NJGM, Kluin-Nelemans HC, van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004;104:143-8.
10. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
11. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
12. Balogh I, Poka R, Pfliegler G, Dekany M, Boda Z, Muszbek L. High prevalence of factor V Leiden mutation and 20210A prothrombin variant in Hungary. Thromb Haemost 1999;81:660-1.
13. Pongracz E, Tordai A, Csornai M, Bela Z, Nagy Z. Significance of Factor V gene A506G mutation (Leiden) in the pathogenesis of ischemic stroke. Ideggyogy Sz 2003;56:157-64.
14. Stankovics J, Melegh B, Nagy A, Kis A, Molnar J, Losonczy H, et al. Incidence of factor V G1681A (Leiden) mutation in samplings from the Hungarian population. Orv Hetil 1998;139:1161-3.
15. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68:1370-3.
16. Schwartz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood 1984;64:1297-300.
17. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965;13:516-30.
18. Tran M, Pharm D, Spencer FA. Thromboepidemiology: identifying patients with heritable risk for thrombin-mediated thromboembolic events. Am Heart J 2005;149:S9-18.
19. Bucciarelli P, Rosendaal FR, Tripodi A, Mannucci PM, De Stefano V, Palareti G, et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999;19:1026-33.
20. Bertina RM. Elevated clotting factor levels and venous thrombosis. Pathophysiol Haemost Thromb 2003/2004;33:399-400.
21. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-62.
22. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-5.
23. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999;81:165-76.
24. Afeltra A, Vadacca M, Conti L, Galluzzo S, Mitterhofer AP, Ferri GM, et al. Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. Arthritis Rheum 2005;53:452-9.
25. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
26. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
27. Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M, et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001;97:844-9.
28. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. The European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period. Medicine 2003;82:299-308.
29. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005;52:2774-82.
30. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232:155-60.
31. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-8.
32. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002;41:924-9.
33. Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med 1996;47:533-53.
34. Galli M, Barbui T. Prevalence of different anti-phospholipid antibodies in systemic lupus erythematosus and their relationship with the antiphospholipid syndrome. Clin Chem 2001;47:985-7.
35. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990;112:682-98.
36. Palomo I, Pereira J, Alarcon M, Larrain AM, Pinochet C, Vasquez M, et al. Antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus. J Lab Clin Med 2002;140:336-41.
37. Radway-Bright EL, Ravirajan CT, Isenberg DA. The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses. Rheumatology (Oxford) 2000;39:427-31.
38. Caccavo D, Del Porto F, Garzia P, Mitterhofer AP, Galluzzo S, Rigon A, et al. Raynaud's phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association? Ann Rheum Dis 2003;62:1003-5.
39. Sebastiani GD, Galeazzi M, Tincani A, Piette JC, Font J, Allegri F, et al. Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol 1999;28:344-51.
40. Gould T, Tikly M, Asherson R, Loizou S, Singh S. Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with systemic lupus erythematosus. Scand J Rheumatol 2006;35:29-34.
41. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
42. Lucotte G, Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 2001;27:362-7.
43. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-5.
44. Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V, et al. Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost 1996;76:883-6.
45. Levine SR, Kieran S, Puzio K, Feit H, Patel SC, Welch KM. Cerebral venous thrombosis with lupus anticoagulants. Report of two cases. Stroke 1987;18:801-4.
46. Levy DM, Massicotte MP, Harvey E, Hebert D, Silverman ED. Thromboembolism in paediatric lupus patients. Lupus 2003;12:741-6.
47. Calvo-Alén J, Toloza SM, Fernández M, Bastian HM, Fessler BJ, Roseman JM, et al. The LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005;52:2060-8.